After HFD treatment, STINGgt mice and mice with destroyed myeloid cells (myeloid cell-specific STING disruption) show less liver steatosis, inflammation, and/or fibrosis, and after transplantation of bone marrow cells from mice in the control group to STINGgt mice, the severity of steatosis and inflammation after HFD can be restored (Luo et al., 2018). The gene discussed is STING1; the disease is Hepatic steatosis.